Search. Learn. Save

Platform for Pharmaceutical Products for Healthcare Professionals
Search By
☰ Generic Formulas

Generic Formulas X

Ceftriaxone

Ceftriaxone: A Cornerstone in Modern Antimicrobial Therapy

Ceftriaxone stands as one of the most trusted and versatile antibiotics in clinical practice today. Belonging to the third-generation cephalosporins, it has gained global recognition for its wide-spectrum activity, excellent pharmacokinetics, and convenient once-daily dosing. Since its introduction in the 1980s, ceftriaxone has become a mainstay in the management of bacterial infections across both inpatient and outpatient settings.

Introduction

Ceftriaxone is a broad-spectrum, third-generation cephalosporin used to treat a variety of infections caused by Gram-positive and Gram-negative bacteria. Its notable features include long half-life, excellent tissue penetration, and resistance to many β-lactamases, making it a go-to option for community-acquired and hospital-acquired infections alike. Approved by the FDA in 1984, ceftriaxone remains on the World Health Organization’s List of Essential Medicines and is widely used in high, middle, and low-income countries.

Chemical and Pharmacological Properties

  • IUPAC Name: (6R,7R)-7-[[(2Z)-(2-Amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-[[(2-methyl-2H-tetrazol-5-yl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

  • Molecular Formula: C18H18N8O7S3

  • Molecular Weight: 554.58 g/mol

  • Class: Third-generation cephalosporin antibiotic

Ceftriaxone is structurally related to other cephalosporins like cefotaxime but has a unique molecular composition that gives it an extended half-life, allowing for once-daily dosing in most cases.

Mechanism of Action

Like other β-lactams, ceftriaxone works by inhibiting bacterial cell wall synthesis. It binds to penicillin-binding proteins (PBPs) inside the bacterial cell wall, preventing the cross-linking of peptidoglycan chains necessary for cell wall strength and integrity.

This leads to:

  • Disruption of the bacterial cell wall

  • Cell lysis

  • Death of the organism

Ceftriaxone is bactericidal and exhibits time-dependent killing, meaning that its efficacy relies on the duration that drug concentration remains above the MIC (Minimum Inhibitory Concentration).

Spectrum of Activity

Ceftriaxone has a broad antimicrobial spectrum, especially strong against Gram-negative organisms and many Gram-positive pathogens.

Gram-Positive Coverage

  • Streptococcus pneumoniae

  • Streptococcus pyogenes (Group A Streptococcus)

  • Streptococcus agalactiae (Group B)

  • Viridans group streptococci

  • MSSA (Methicillin-sensitive Staphylococcus aureus) – moderate

Gram-Negative Coverage

  • Neisseria gonorrhoeae

  • Neisseria meningitidis

  • Haemophilus influenzae

  • Escherichia coli

  • Klebsiella pneumoniae

  • Proteus mirabilis

  • Salmonella, Shigella species

Limited or No Activity

  • MRSA (Methicillin-resistant Staphylococcus aureus)

  • Pseudomonas aeruginosa

  • Enterococcus spp.

  • Anaerobes (generally poor, except Fusobacterium and Prevotella)

Pharmacokinetics

Absorption and Distribution

  • Administered IV or IM due to poor oral bioavailability

  • Excellent tissue penetration, including:

    • CSF (especially in meningitis)

    • Bone

    • Pleural fluid

    • Synovial fluid

Half-Life

  • Long half-life of 6–9 hours

  • Allows for once-daily dosing in most infections

Protein Binding

  • Highly bound to albumin (~85-95%)

Excretion

  • Dual route: Renal and biliary excretion

  • No need for dose adjustment in mild to moderate renal dysfunction

Dosage and Administration

Adults

  • Standard: 1–2 g once daily

  • Severe infections: 2 g every 12 hours

Children

  • 50–100 mg/kg/day IV/IM, divided in 1–2 doses

Special Cases

  • Gonorrhea: 500 mg IM single dose

  • Meningitis: 2 g IV every 12 hours

  • Surgical prophylaxis: 1 g IV 30–60 minutes before incision

Clinical Indications

Ceftriaxone’s versatility allows it to be used in numerous infectious diseases:

1. Lower Respiratory Tract Infections

  • Community-acquired pneumonia

  • Hospital-acquired pneumonia (as part of combination therapy)

2. Meningitis

  • Excellent CSF penetration

  • Effective against N. meningitidis, H. influenzae, and S. pneumoniae

3. Urinary Tract Infections (UTIs)

  • Especially complicated cases or pyelonephritis

4. Gonorrhea

  • First-line treatment for N. gonorrhoeae infections

5. Skin and Soft Tissue Infections

6. Intra-abdominal Infections

  • Usually in combination with metronidazole

7. Sepsis and Bacteremia

  • Effective against many causative organisms, especially when sensitivities are known

8. Surgical Prophylaxis

9. Otitis Media and Sinusitis

Adverse Effects

Ceftriaxone is generally well tolerated, but adverse effects can occur:

Common

  • Diarrhea

  • Rash

  • Injection site reactions

  • Nausea

Serious or Rare

  • Anaphylaxis

  • Hemolytic anemia

  • Cholelithiasis and biliary sludge (especially in children)

  • Neutropenia or thrombocytopenia

  • C. difficile-associated diarrhea

Warnings

  • Avoid calcium-containing IV solutions in neonates (risk of precipitate formation)

Drug Interactions

  • Calcium-containing IV products: Risk of fatal lung and kidney precipitation in neonates

  • Warfarin: May increase INR – monitor closely

  • Probenecid: May reduce clearance, though less relevant than with other β-lactams

Use in Special Populations

Pregnancy

  • Category B – safe in pregnancy

Lactation

  • Small amounts excreted in breast milk – considered safe

Pediatrics

  • Commonly used, but caution in neonates due to risk of kernicterus and calcium precipitation

Renal and Hepatic Impairment

  • Dose adjustment usually not needed unless both organ systems are impaired

Resistance Considerations

Mechanisms of Resistance

  1. β-lactamase production – ESBLs and AmpC enzymes

  2. Altered PBPs – common in Streptococcus pneumoniae

  3. Porin channel mutations and efflux pumps – particularly in Gram-negatives

Rising Concerns

  • Emergence of cephalosporin-resistant N. gonorrhoeae

  • ESBL-producing Enterobacteriaceae

  • Carbapenem-resistant organisms show cross-resistance

Judicious use of ceftriaxone is critical to preserve its effectiveness.

Comparison with Other Cephalosporins

Cephalosporin Generation Route Half-life Spectrum Pseudomonas Coverage
Ceftriaxone 3rd IV/IM 6–9 hrs Broad No
Cefotaxime 3rd IV/IM 1 hr Broad No
Ceftazidime 3rd IV/IM 1.5–2 hrs Broad Yes
Cefepime 4th IV 2 hrs Broad Yes

Ceftriaxone's long half-life gives it a significant advantage in terms of convenience and compliance.

Global Usage and Guidelines

  • WHO: Listed as an essential medicine

  • CDC: Recommended for gonorrhea and bacterial meningitis

  • IDSA Guidelines:

    • First-line in S. pneumoniae meningitis

    • Used in community-acquired pneumonia with a macrolide

In many low- and middle-income countries, ceftriaxone is the backbone of empiric therapy due to its affordability and effectiveness.

Formulations and Brands

  • Available as vials for injection in various strengths (250 mg, 500 mg, 1 g, 2 g)

  • Common brands: Rocephin, Ceftrisol, Traxon, Monocef

Storage and Handling

  • Store the powder at room temperature

  • Reconstituted solutions should be used promptly or refrigerated and used within 24 hours (IV) or 48 hours (IM)

Conclusion

Ceftriaxone is a cornerstone antibiotic in modern medicine, offering broad-spectrum activity, excellent tolerability, and the convenience of once-daily dosing. Its clinical efficacy across a range of infections—from meningitis to pneumonia, from sepsis to gonorrhea—makes it a critical part of the antimicrobial arsenal. However, increasing resistance patterns and global misuse pose threats to its continued effectiveness. Stewardship, susceptibility testing, and adherence to treatment guidelines are essential to ensure ceftriaxone remains an effective option in the fight against bacterial infections.